J.P. Maffrand

4.6k total citations · 1 hit paper
56 papers, 3.9k citations indexed

About

J.P. Maffrand is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Surgery. According to data from OpenAlex, J.P. Maffrand has authored 56 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Cardiology and Cardiovascular Medicine, 16 papers in Molecular Biology and 9 papers in Surgery. Recurrent topics in J.P. Maffrand's work include Antiplatelet Therapy and Cardiovascular Diseases (14 papers), Neuropeptides and Animal Physiology (8 papers) and Receptor Mechanisms and Signaling (8 papers). J.P. Maffrand is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (14 papers), Neuropeptides and Animal Physiology (8 papers) and Receptor Mechanisms and Signaling (8 papers). J.P. Maffrand collaborates with scholars based in France, Italy and United States. J.P. Maffrand's co-authors include Jean‐Marc Herbert, Jean‐Michel Augereau, J. Gleye, G. Le Fur, Philippe Soubrié, A. Bernat, Magali Gary‐Bobo, Florence Oury-Donat, M. Bensaïd and Pierre Savi and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Investigation.

In The Last Decade

J.P. Maffrand

56 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chelerythrine is a potent and specific inhibitor of protein kinase C

1990 1.1k citations Jean‐Marc Herbert, J.P. Maffrand et al. profile →

Peers

Countries citing papers authored by J.P. Maffrand

Since Specialization

Citations

This map shows the geographic impact of J.P. Maffrand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.P. Maffrand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.P. Maffrand more than expected).

Fields of papers citing papers by J.P. Maffrand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.P. Maffrand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.P. Maffrand. The network helps show where J.P. Maffrand may publish in the future.

Co-authorship network of co-authors of J.P. Maffrand

This figure shows the co-authorship network connecting the top 25 collaborators of J.P. Maffrand. A scholar is included among the top collaborators of J.P. Maffrand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.P. Maffrand. J.P. Maffrand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats 2007 ·Kidney International ·Philip Janiak, Bruno Poirier, Jean‐Pierre Bidouard, (unknown), (unknown), (unknown), Isabelle Barbosa, Jürgen Dedio, J.P. Maffrand, G. Le Fur, Stephen O’Connor, Jean Marc Herbert	107
2	IN VITRO METABOLISM OF FERROQUINE (SSR97193) IN ANIMAL AND HUMAN HEPATIC MODELS AND ANTIMALARIAL ACTIVITY OF MAJOR METABOLITES ON PLASMODIUM FALCIPARUM 2006 ·Drug Metabolism and Disposition ·Wassim Daher, Lydie Pélinski, Sylvie Klieber, (unknown), Viviane Meunier, Martine Bourrié, Christophe Biot, F. Guillou, Gérard Fabre, Jacques Brocard, Laurent Fraisse, J.P. Maffrand, Jamal Khalife, Daniel Dive	24
3	Chapter 15 Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands 2002 ·Progress in brain research ·(unknown), Jean Wagnon, G Valette, Gabriela Garcia, Marc Pascal, J.P. Maffrand, G. Le Fur	76
4	In vitro functional evidence of different neurotensin‐receptors modulating the motor response of human colonic muscle strips 1999 ·British Journal of Pharmacology ·Tiziano Croci, (unknown), Fabio Guagnini, L. Manara, (unknown), Gérard Le Fur, J.P. Maffrand, Sylvain Mukenge, Gianfranco Ferla, Pascual Ferrara, Pascale Chalon, Natalio Vita	10
5	The cloned guinea pig neuropeptide Y receptor Y1 conforms to other mammalian Y1 receptors 1999 ·Peptides ·Magnus Berglund, Sara K.S. Holmberg, (unknown), Karin Gedda, J.P. Maffrand, (unknown), Vijay Chhajlani, Lars Grundemar, Dan Larhammar	32
6	In vitro functional evidence of neuronal cannabinoid CB₁ receptors in human ileum 1998 ·British Journal of Pharmacology ·Tiziano Croci, L. Manara, (unknown), Fabio Guagnini, Murielle Rinaldi‐Carmona, J.P. Maffrand, Gérard Le Fur, Sylvain Mukenge, Gianfranco Ferla	132
7	Effect of the neurotensin receptor antagonist SR48692 on rat blood pressure modulation by neurotensin 1996 ·Life Sciences ·D. Gully, (unknown), (unknown), William Rostène, Patrick Kitabgi, G. Le Fur, J.P. Maffrand	16
8	Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059 1996 ·Kidney International ·(unknown), Danielle Raufaste, (unknown), (unknown), J.P. Maffrand, Gérard Le Fur	30
9	Purification and characterization of a novel protease from culture filtrates of aStreptomycessp. 1996 ·FEMS Microbiology Letters ·(unknown), Pierre Savi, (unknown), Mohamed Maftouh, Jean‐Marie Pereillo, Joël Capdevielle, Jean‐Claude Guillemot, J.P. Maffrand, Jean-Marc Herbert	9
10	The Antiaggregating and Antithrombotic Activity of Ticlopidine Is Potentiated by Aspirin in the Rat 1996 ·Thrombosis and Haemostasis ·Jean‐Marc Herbert, A. Bernat, M. Samama, J.P. Maffrand	39
11	Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine. 1994 ·Journal of Pharmacology and Experimental Therapeutics ·Pierre Savi, Marie-Claude Laplace, J.P. Maffrand, Jean‐Marc Herbert	95
12	Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on swiss 3T3 cells 1994 ·Biochemical Pharmacology ·C. Serradeil‐Le Gal, B. Bourrié, Danielle Raufaste, P Carayon, Corinne Garcia, J.P. Maffrand, G. Le Fur, Pierre Casellas	26
13	Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. 1993 ·Journal of Clinical Investigation ·C. Serradeil‐Le Gal, Jean Wagnon, Corinne Garcia, C Lacour, P. Guiraudou, B. Christophe, G. Villanova, Dino Nisato, J.P. Maffrand, G. Le Fur	245
14	SR 27417, a highly potent, selective and long-acting antagonist of the PAF receptor 1992 ·Drugs of the Future ·Jean Marc Herbert, G Valette, A. Bernat, Pierre Savi, J.P. Maffrand, G. Le Fur	6
15	The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1 1990 ·Biochemical Pharmacology ·Christian Gachet, Jean‐Pierre Cazenave, Philippe Ohlmann, (unknown), (unknown), (unknown), J.P. Maffrand	51
16	Production and Evaluation of Recombinant Hirudin 1989 ·Seminars in Thrombosis and Hemostasis ·Michael Courtney, G. Loison, Yves Lemoine, (unknown), Eric Degryse, Stephen Brown, Jean‐Pierre Cazenave, G. Defreyn, Denis Delebassée, A. Bernat, J.P. Maffrand, Carolyn Roitsch	15
17	Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin 1989 ·Protein Engineering Design and Selection ·Eric Degryse, Michael Acker, G. Defreyn, A. Bernat, J.P. Maffrand, Carolyn Roitsch, Michael Courtney	34
18	Pharmacology of Ticlopidine: A Review 1989 ·Seminars in Thrombosis and Hemostasis ·(unknown), A. Bernat, Denis Delebassée, J.P. Maffrand	61
19	Pharmacokinetics of 125I-pentosan polysulfate in the rabbit 1987 ·Thrombosis Research ·(unknown), F. Dol, C. Caranobe, Piérre Siè, Georges Houin, C. Picard, Jean‐Marie Pereillo, J.P. Maffrand, B Boneu	3
20	Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP 1987 ·Thrombosis Research ·(unknown), Denis Delebassée, Michel Simon, Hugues Chap, G. Defreyn, E. Vallée, Louis Douste‐Blazy, J.P. Maffrand	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact